Clinicoradiologic predictors of sclerotherapy response in low-flow vascular malformations.
Adolescent
Adult
Child
Child, Preschool
Cross-Sectional Studies
Female
Humans
Lymphatic Abnormalities
/ diagnostic imaging
Male
Middle Aged
Phlebography
Regional Blood Flow
Retrospective Studies
Sclerosing Solutions
/ adverse effects
Sclerotherapy
/ adverse effects
Time Factors
Treatment Outcome
Vascular Malformations
/ diagnostic imaging
Veins
/ abnormalities
Young Adult
Low-flow vascular malformations
Lymphatic malformations
Phlebography
Sclerotherapy
Venous malformations
Journal
Journal of vascular surgery. Venous and lymphatic disorders
ISSN: 2213-3348
Titre abrégé: J Vasc Surg Venous Lymphat Disord
Pays: United States
ID NLM: 101607771
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
27
12
2019
accepted:
19
03
2020
pubmed:
13
7
2020
medline:
29
4
2021
entrez:
13
7
2020
Statut:
ppublish
Résumé
To evaluate the clinical effectiveness of sclerotherapy agents in low-flow vascular malformations (LFVM) and identify clinical/imaging features to predict response. A retrospective analysis of hospital records of symptomatic LFVM patients who underwent phlebosclerotherapy from January 2015 to April 2018 was done. Patients were subdivided into venous malformations (VM) and lymphatic malformations (LM). Out of 246 cases, 223 patients (132 males, 91 females; age range, 2-52 years) had VM and 23 (13 males, 10 females; age range, 3 months to 45 years) had LM. The clinical response was graded as excellent (>60%), good (30%-60%), and poor (<30%). More than 30% was considered as acceptable response. The χ Cavitary (43%) and spongy (37.7%) were the most common phlebographic patterns seen among VM and a cavitary pattern (87%) was most frequent in LM. Sodium tetradecyl sulphate and bleomycin were most commonly used sclerosants in VM and LM, respectively. The mean number of sessions was 4.35 (range, 1-23) in VM and 2.64 (range, 2-7) in LM. Among VM, 114 patients (51.1%) had excellent response to treatment (>60%) and 75.8% patients had an acceptable response (>30%). All patients with LM had an acceptable response (excellent response in 86.9%). Clinical disfigurement, discoloration, diffuse involvement, dysplastic venous morphology on phlebogram, and late and indirect draining vein correlated with poor response to sclerotherapy in VM (P = .003, P = .036, P = .007, P = .008, P = .003, and P = .035, respectively). Cystic components on ultrasound examination and direct draining vein were seen more often in excellent responders (P = .004 and P = .007) in addition to absence of disfigurement, discoloration, and diffuse involvement (P = .032, P = .003, and P = .002). Mod els comprising clinical disfigurement, dysplastic veins, and late draining vein had the greatest predictive value for poor response (R Acceptable response to sclerotherapy was achieved in majority of LFVM with extremely low complication rates. Clinicoradiologic features, especially phlebographic findings, correlated with response to sclerotherapy.
Identifiants
pubmed: 32653406
pii: S2213-333X(20)30202-X
doi: 10.1016/j.jvsv.2020.03.011
pii:
doi:
Substances chimiques
Sclerosing Solutions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-219.e2Informations de copyright
Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.